Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs SiTime Corporation (SITM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs SiTime Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while SiTime Corporation trades at $619.94 (market cap $18.83B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.1× SiTime Corporation's market cap, and SiTime Corporation is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SITM | |
|---|---|---|
Market Cap | $39.89B | $18.83B |
Sector | Health | Technology |
52-Week High | $491.22 | $901.60 |
52-Week Low | $278.09 | $190.16 |
Enterprise Value | $38.15B | $18.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SITM trades at $628.94, down 2.96% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth and consistent earnings beats, with Q1 2026 EPS of $1.44 surpassing estimates. Recent acquisition of Renesas' timing business and raised AI-driven growth guidance highlight strategic expansion. However, negative net income margins and high P/S ratio of 42.42 indicate valuation concerns amid profitability challenges.
Outlook remains positive with 100% analyst buy ratings and a $743.75 consensus target, suggesting 18% upside. Key risks include sustained unprofitability, integration execution from acquisitions, and market volatility. The stock's trajectory hinges on achieving projected 2026 profitability improvements and capitalizing on AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
